Pharma & Healthcare
Remicade (Infliximab) Monoclonal Antibody - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
- Nov 05, 24
- ID: 660553
- Pages: 83
- Figures: 189
- Views: 5
Infliximab is a monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. Avsola, Flixabi, Inflectra, Remicade, Renflexis.
The global market for Remicade (Infliximab) Monoclonal Antibody was estimated to be worth US$ 2550 million in 2023 and is forecast to a readjusted size of US$ 3855 million by 2030 with a CAGR of 5.6% during the forecast period 2024-2030
The Remicade (Infliximab) monoclonal antibody market is driven by several factors. One of the primary drivers is the high prevalence of chronic autoimmune diseases, such as rheumatoid arthritis, Crohn's disease, and psoriasis, which require targeted immunotherapy for effective management. Remicade, as a monoclonal antibody, has demonstrated significant efficacy in treating these conditions by specifically targeting and inhibiting tumor necrosis factor-alpha (TNF-alpha), a key mediator of inflammation. Additionally, the increasing adoption of biologic therapies, including monoclonal antibodies, in clinical practice has fueled the demand for Remicade. The proven clinical efficacy, long-term safety profile, and established therapeutic outcomes have contributed to its market growth. Moreover, the expanding patient pool, coupled with the rising awareness and diagnosis rates of autoimmune diseases, has created a greater demand for targeted biologic treatments like Remicade. Furthermore, the presence of robust research and development activities aimed at developing novel monoclonal antibodies and exploring new indications for Remicade continues to drive market growth. Overall, the Remicade monoclonal antibody market is driven by the high prevalence of autoimmune diseases, increasing adoption of biologic therapies, established clinical efficacy, expanding patient pool, and ongoing research and development efforts.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Remicade (Infliximab) Monoclonal Antibody, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Remicade (Infliximab) Monoclonal Antibody by region & country, by Type, and by Application.
The Remicade (Infliximab) Monoclonal Antibody market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Remicade (Infliximab) Monoclonal Antibody.
Market Segmentation
By Company
J & J
Pfizer
Organon
Amgen
Segment by Type:
Brand
Biosimilar
Segment by Application
Ankylosing Spondylitis
Rheumatoid Arthritis
Crohn’s Disease
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Remicade (Infliximab) Monoclonal Antibody manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Remicade (Infliximab) Monoclonal Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Remicade (Infliximab) Monoclonal Antibody in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global market for Remicade (Infliximab) Monoclonal Antibody was estimated to be worth US$ 2550 million in 2023 and is forecast to a readjusted size of US$ 3855 million by 2030 with a CAGR of 5.6% during the forecast period 2024-2030
The Remicade (Infliximab) monoclonal antibody market is driven by several factors. One of the primary drivers is the high prevalence of chronic autoimmune diseases, such as rheumatoid arthritis, Crohn's disease, and psoriasis, which require targeted immunotherapy for effective management. Remicade, as a monoclonal antibody, has demonstrated significant efficacy in treating these conditions by specifically targeting and inhibiting tumor necrosis factor-alpha (TNF-alpha), a key mediator of inflammation. Additionally, the increasing adoption of biologic therapies, including monoclonal antibodies, in clinical practice has fueled the demand for Remicade. The proven clinical efficacy, long-term safety profile, and established therapeutic outcomes have contributed to its market growth. Moreover, the expanding patient pool, coupled with the rising awareness and diagnosis rates of autoimmune diseases, has created a greater demand for targeted biologic treatments like Remicade. Furthermore, the presence of robust research and development activities aimed at developing novel monoclonal antibodies and exploring new indications for Remicade continues to drive market growth. Overall, the Remicade monoclonal antibody market is driven by the high prevalence of autoimmune diseases, increasing adoption of biologic therapies, established clinical efficacy, expanding patient pool, and ongoing research and development efforts.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Remicade (Infliximab) Monoclonal Antibody, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Remicade (Infliximab) Monoclonal Antibody by region & country, by Type, and by Application.
The Remicade (Infliximab) Monoclonal Antibody market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Remicade (Infliximab) Monoclonal Antibody.
Market Segmentation
By Company
J & J
Pfizer
Organon
Amgen
Segment by Type:
Brand
Biosimilar
Segment by Application
Ankylosing Spondylitis
Rheumatoid Arthritis
Crohn’s Disease
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Remicade (Infliximab) Monoclonal Antibody manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Remicade (Infliximab) Monoclonal Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Remicade (Infliximab) Monoclonal Antibody in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
1 Market Overview
1.1 Remicade (Infliximab) Monoclonal Antibody Product Introduction
1.2 Global Remicade (Infliximab) Monoclonal Antibody Market Size Forecast
1.2.1 Global Remicade (Infliximab) Monoclonal Antibody Sales Value (2019-2030)
1.2.2 Global Remicade (Infliximab) Monoclonal Antibody Sales Volume (2019-2030)
1.2.3 Global Remicade (Infliximab) Monoclonal Antibody Sales Price (2019-2030)
1.3 Remicade (Infliximab) Monoclonal Antibody Market Trends & Drivers
1.3.1 Remicade (Infliximab) Monoclonal Antibody Industry Trends
1.3.2 Remicade (Infliximab) Monoclonal Antibody Market Drivers & Opportunity
1.3.3 Remicade (Infliximab) Monoclonal Antibody Market Challenges
1.3.4 Remicade (Infliximab) Monoclonal Antibody Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Remicade (Infliximab) Monoclonal Antibody Players Revenue Ranking (2023)
2.2 Global Remicade (Infliximab) Monoclonal Antibody Revenue by Company (2019-2024)
2.3 Global Remicade (Infliximab) Monoclonal Antibody Players Sales Volume Ranking (2023)
2.4 Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Company Players (2019-2024)
2.5 Global Remicade (Infliximab) Monoclonal Antibody Average Price by Company (2019-2024)
2.6 Key Manufacturers Remicade (Infliximab) Monoclonal Antibody Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Remicade (Infliximab) Monoclonal Antibody Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Remicade (Infliximab) Monoclonal Antibody
2.9 Remicade (Infliximab) Monoclonal Antibody Market Competitive Analysis
2.9.1 Remicade (Infliximab) Monoclonal Antibody Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Remicade (Infliximab) Monoclonal Antibody Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Remicade (Infliximab) Monoclonal Antibody as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Brand
3.1.2 Biosimilar
3.2 Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Type
3.2.1 Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Remicade (Infliximab) Monoclonal Antibody Sales Value, by Type (2019-2030)
3.2.3 Global Remicade (Infliximab) Monoclonal Antibody Sales Value, by Type (%) (2019-2030)
3.3 Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Type
3.3.1 Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Remicade (Infliximab) Monoclonal Antibody Sales Volume, by Type (2019-2030)
3.3.3 Global Remicade (Infliximab) Monoclonal Antibody Sales Volume, by Type (%) (2019-2030)
3.4 Global Remicade (Infliximab) Monoclonal Antibody Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Ankylosing Spondylitis
4.1.2 Rheumatoid Arthritis
4.1.3 Crohn’s Disease
4.1.4 Other
4.2 Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Application
4.2.1 Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Remicade (Infliximab) Monoclonal Antibody Sales Value, by Application (2019-2030)
4.2.3 Global Remicade (Infliximab) Monoclonal Antibody Sales Value, by Application (%) (2019-2030)
4.3 Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Application
4.3.1 Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Remicade (Infliximab) Monoclonal Antibody Sales Volume, by Application (2019-2030)
4.3.3 Global Remicade (Infliximab) Monoclonal Antibody Sales Volume, by Application (%) (2019-2030)
4.4 Global Remicade (Infliximab) Monoclonal Antibody Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Region
5.1.1 Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Region (2019-2024)
5.1.3 Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Region (2025-2030)
5.1.4 Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Region (%), (2019-2030)
5.2 Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Region
5.2.1 Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Region (2019-2024)
5.2.3 Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Region (2025-2030)
5.2.4 Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Region (%), (2019-2030)
5.3 Global Remicade (Infliximab) Monoclonal Antibody Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Remicade (Infliximab) Monoclonal Antibody Sales Value, 2019-2030
5.4.2 North America Remicade (Infliximab) Monoclonal Antibody Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Remicade (Infliximab) Monoclonal Antibody Sales Value, 2019-2030
5.5.2 Europe Remicade (Infliximab) Monoclonal Antibody Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Remicade (Infliximab) Monoclonal Antibody Sales Value, 2019-2030
5.6.2 Asia Pacific Remicade (Infliximab) Monoclonal Antibody Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Remicade (Infliximab) Monoclonal Antibody Sales Value, 2019-2030
5.7.2 South America Remicade (Infliximab) Monoclonal Antibody Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Sales Value, 2019-2030
5.8.2 Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Remicade (Infliximab) Monoclonal Antibody Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Remicade (Infliximab) Monoclonal Antibody Sales Value
6.2.1 Key Countries/Regions Remicade (Infliximab) Monoclonal Antibody Sales Value, 2019-2030
6.2.2 Key Countries/Regions Remicade (Infliximab) Monoclonal Antibody Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Remicade (Infliximab) Monoclonal Antibody Sales Value, 2019-2030
6.3.2 United States Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Remicade (Infliximab) Monoclonal Antibody Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Remicade (Infliximab) Monoclonal Antibody Sales Value, 2019-2030
6.4.2 Europe Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Remicade (Infliximab) Monoclonal Antibody Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Remicade (Infliximab) Monoclonal Antibody Sales Value, 2019-2030
6.5.2 China Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (%), 2023 VS 2030
6.5.3 China Remicade (Infliximab) Monoclonal Antibody Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Remicade (Infliximab) Monoclonal Antibody Sales Value, 2019-2030
6.6.2 Japan Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Remicade (Infliximab) Monoclonal Antibody Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Remicade (Infliximab) Monoclonal Antibody Sales Value, 2019-2030
6.7.2 South Korea Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Remicade (Infliximab) Monoclonal Antibody Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Remicade (Infliximab) Monoclonal Antibody Sales Value, 2019-2030
6.8.2 Southeast Asia Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Remicade (Infliximab) Monoclonal Antibody Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Remicade (Infliximab) Monoclonal Antibody Sales Value, 2019-2030
6.9.2 India Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (%), 2023 VS 2030
6.9.3 India Remicade (Infliximab) Monoclonal Antibody Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 J & J
7.1.1 J & J Company Information
7.1.2 J & J Introduction and Business Overview
7.1.3 J & J Remicade (Infliximab) Monoclonal Antibody Sales, Revenue and Gross Margin (2019-2024)
7.1.4 J & J Remicade (Infliximab) Monoclonal Antibody Product Offerings
7.1.5 J & J Recent Development
7.2 Pfizer
7.2.1 Pfizer Company Information
7.2.2 Pfizer Introduction and Business Overview
7.2.3 Pfizer Remicade (Infliximab) Monoclonal Antibody Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Pfizer Remicade (Infliximab) Monoclonal Antibody Product Offerings
7.2.5 Pfizer Recent Development
7.3 Organon
7.3.1 Organon Company Information
7.3.2 Organon Introduction and Business Overview
7.3.3 Organon Remicade (Infliximab) Monoclonal Antibody Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Organon Remicade (Infliximab) Monoclonal Antibody Product Offerings
7.3.5 Organon Recent Development
7.4 Amgen
7.4.1 Amgen Company Information
7.4.2 Amgen Introduction and Business Overview
7.4.3 Amgen Remicade (Infliximab) Monoclonal Antibody Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Amgen Remicade (Infliximab) Monoclonal Antibody Product Offerings
7.4.5 Amgen Recent Development
8 Industry Chain Analysis
8.1 Remicade (Infliximab) Monoclonal Antibody Industrial Chain
8.2 Remicade (Infliximab) Monoclonal Antibody Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Remicade (Infliximab) Monoclonal Antibody Sales Model
8.5.2 Sales Channel
8.5.3 Remicade (Infliximab) Monoclonal Antibody Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
1.1 Remicade (Infliximab) Monoclonal Antibody Product Introduction
1.2 Global Remicade (Infliximab) Monoclonal Antibody Market Size Forecast
1.2.1 Global Remicade (Infliximab) Monoclonal Antibody Sales Value (2019-2030)
1.2.2 Global Remicade (Infliximab) Monoclonal Antibody Sales Volume (2019-2030)
1.2.3 Global Remicade (Infliximab) Monoclonal Antibody Sales Price (2019-2030)
1.3 Remicade (Infliximab) Monoclonal Antibody Market Trends & Drivers
1.3.1 Remicade (Infliximab) Monoclonal Antibody Industry Trends
1.3.2 Remicade (Infliximab) Monoclonal Antibody Market Drivers & Opportunity
1.3.3 Remicade (Infliximab) Monoclonal Antibody Market Challenges
1.3.4 Remicade (Infliximab) Monoclonal Antibody Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Remicade (Infliximab) Monoclonal Antibody Players Revenue Ranking (2023)
2.2 Global Remicade (Infliximab) Monoclonal Antibody Revenue by Company (2019-2024)
2.3 Global Remicade (Infliximab) Monoclonal Antibody Players Sales Volume Ranking (2023)
2.4 Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Company Players (2019-2024)
2.5 Global Remicade (Infliximab) Monoclonal Antibody Average Price by Company (2019-2024)
2.6 Key Manufacturers Remicade (Infliximab) Monoclonal Antibody Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Remicade (Infliximab) Monoclonal Antibody Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Remicade (Infliximab) Monoclonal Antibody
2.9 Remicade (Infliximab) Monoclonal Antibody Market Competitive Analysis
2.9.1 Remicade (Infliximab) Monoclonal Antibody Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Remicade (Infliximab) Monoclonal Antibody Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Remicade (Infliximab) Monoclonal Antibody as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Brand
3.1.2 Biosimilar
3.2 Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Type
3.2.1 Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Remicade (Infliximab) Monoclonal Antibody Sales Value, by Type (2019-2030)
3.2.3 Global Remicade (Infliximab) Monoclonal Antibody Sales Value, by Type (%) (2019-2030)
3.3 Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Type
3.3.1 Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Remicade (Infliximab) Monoclonal Antibody Sales Volume, by Type (2019-2030)
3.3.3 Global Remicade (Infliximab) Monoclonal Antibody Sales Volume, by Type (%) (2019-2030)
3.4 Global Remicade (Infliximab) Monoclonal Antibody Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Ankylosing Spondylitis
4.1.2 Rheumatoid Arthritis
4.1.3 Crohn’s Disease
4.1.4 Other
4.2 Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Application
4.2.1 Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Remicade (Infliximab) Monoclonal Antibody Sales Value, by Application (2019-2030)
4.2.3 Global Remicade (Infliximab) Monoclonal Antibody Sales Value, by Application (%) (2019-2030)
4.3 Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Application
4.3.1 Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Remicade (Infliximab) Monoclonal Antibody Sales Volume, by Application (2019-2030)
4.3.3 Global Remicade (Infliximab) Monoclonal Antibody Sales Volume, by Application (%) (2019-2030)
4.4 Global Remicade (Infliximab) Monoclonal Antibody Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Region
5.1.1 Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Region (2019-2024)
5.1.3 Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Region (2025-2030)
5.1.4 Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Region (%), (2019-2030)
5.2 Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Region
5.2.1 Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Region (2019-2024)
5.2.3 Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Region (2025-2030)
5.2.4 Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Region (%), (2019-2030)
5.3 Global Remicade (Infliximab) Monoclonal Antibody Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Remicade (Infliximab) Monoclonal Antibody Sales Value, 2019-2030
5.4.2 North America Remicade (Infliximab) Monoclonal Antibody Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Remicade (Infliximab) Monoclonal Antibody Sales Value, 2019-2030
5.5.2 Europe Remicade (Infliximab) Monoclonal Antibody Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Remicade (Infliximab) Monoclonal Antibody Sales Value, 2019-2030
5.6.2 Asia Pacific Remicade (Infliximab) Monoclonal Antibody Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Remicade (Infliximab) Monoclonal Antibody Sales Value, 2019-2030
5.7.2 South America Remicade (Infliximab) Monoclonal Antibody Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Sales Value, 2019-2030
5.8.2 Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Remicade (Infliximab) Monoclonal Antibody Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Remicade (Infliximab) Monoclonal Antibody Sales Value
6.2.1 Key Countries/Regions Remicade (Infliximab) Monoclonal Antibody Sales Value, 2019-2030
6.2.2 Key Countries/Regions Remicade (Infliximab) Monoclonal Antibody Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Remicade (Infliximab) Monoclonal Antibody Sales Value, 2019-2030
6.3.2 United States Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Remicade (Infliximab) Monoclonal Antibody Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Remicade (Infliximab) Monoclonal Antibody Sales Value, 2019-2030
6.4.2 Europe Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Remicade (Infliximab) Monoclonal Antibody Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Remicade (Infliximab) Monoclonal Antibody Sales Value, 2019-2030
6.5.2 China Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (%), 2023 VS 2030
6.5.3 China Remicade (Infliximab) Monoclonal Antibody Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Remicade (Infliximab) Monoclonal Antibody Sales Value, 2019-2030
6.6.2 Japan Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Remicade (Infliximab) Monoclonal Antibody Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Remicade (Infliximab) Monoclonal Antibody Sales Value, 2019-2030
6.7.2 South Korea Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Remicade (Infliximab) Monoclonal Antibody Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Remicade (Infliximab) Monoclonal Antibody Sales Value, 2019-2030
6.8.2 Southeast Asia Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Remicade (Infliximab) Monoclonal Antibody Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Remicade (Infliximab) Monoclonal Antibody Sales Value, 2019-2030
6.9.2 India Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (%), 2023 VS 2030
6.9.3 India Remicade (Infliximab) Monoclonal Antibody Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 J & J
7.1.1 J & J Company Information
7.1.2 J & J Introduction and Business Overview
7.1.3 J & J Remicade (Infliximab) Monoclonal Antibody Sales, Revenue and Gross Margin (2019-2024)
7.1.4 J & J Remicade (Infliximab) Monoclonal Antibody Product Offerings
7.1.5 J & J Recent Development
7.2 Pfizer
7.2.1 Pfizer Company Information
7.2.2 Pfizer Introduction and Business Overview
7.2.3 Pfizer Remicade (Infliximab) Monoclonal Antibody Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Pfizer Remicade (Infliximab) Monoclonal Antibody Product Offerings
7.2.5 Pfizer Recent Development
7.3 Organon
7.3.1 Organon Company Information
7.3.2 Organon Introduction and Business Overview
7.3.3 Organon Remicade (Infliximab) Monoclonal Antibody Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Organon Remicade (Infliximab) Monoclonal Antibody Product Offerings
7.3.5 Organon Recent Development
7.4 Amgen
7.4.1 Amgen Company Information
7.4.2 Amgen Introduction and Business Overview
7.4.3 Amgen Remicade (Infliximab) Monoclonal Antibody Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Amgen Remicade (Infliximab) Monoclonal Antibody Product Offerings
7.4.5 Amgen Recent Development
8 Industry Chain Analysis
8.1 Remicade (Infliximab) Monoclonal Antibody Industrial Chain
8.2 Remicade (Infliximab) Monoclonal Antibody Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Remicade (Infliximab) Monoclonal Antibody Sales Model
8.5.2 Sales Channel
8.5.3 Remicade (Infliximab) Monoclonal Antibody Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Remicade (Infliximab) Monoclonal Antibody Market Trends
Table 2. Remicade (Infliximab) Monoclonal Antibody Market Drivers & Opportunity
Table 3. Remicade (Infliximab) Monoclonal Antibody Market Challenges
Table 4. Remicade (Infliximab) Monoclonal Antibody Market Restraints
Table 5. Global Remicade (Infliximab) Monoclonal Antibody Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Remicade (Infliximab) Monoclonal Antibody Revenue Market Share by Company (2019-2024)
Table 7. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Company (2019-2024) & (K Units)
Table 8. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume Market Share by Company (2019-2024)
Table 9. Global Market Remicade (Infliximab) Monoclonal Antibody Price by Company (2019-2024) & (US$/Unit)
Table 10. Key Manufacturers Remicade (Infliximab) Monoclonal Antibody Manufacturing Base Distribution and Headquarters
Table 11. Key Manufacturers Remicade (Infliximab) Monoclonal Antibody Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Remicade (Infliximab) Monoclonal Antibody
Table 13. Global Remicade (Infliximab) Monoclonal Antibody Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Remicade (Infliximab) Monoclonal Antibody as of 2023)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share in Value by Type (2019-2024) & (%)
Table 20. Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share in Value by Type (2025-2030) & (%)
Table 21. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
Table 22. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Type (2019-2024) & (K Units)
Table 23. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Type (2025-2030) & (K Units)
Table 24. Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share in Volume by Type (2019-2024) & (%)
Table 25. Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share in Volume by Type (2025-2030) & (%)
Table 26. Global Remicade (Infliximab) Monoclonal Antibody Price by Type (2019-2024) & (US$/Unit)
Table 27. Global Remicade (Infliximab) Monoclonal Antibody Price by Type (2025-2030) & (US$/Unit)
Table 28. Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Application (2019-2024) & (US$ Million)
Table 30. Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Application (2025-2030) & (US$ Million)
Table 31. Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share in Value by Application (2019-2024) & (%)
Table 32. Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share in Value by Application (2025-2030) & (%)
Table 33. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
Table 34. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Application (2019-2024) & (K Units)
Table 35. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Application (2025-2030) & (K Units)
Table 36. Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share in Volume by Application (2019-2024) & (%)
Table 37. Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share in Volume by Application (2025-2030) & (%)
Table 38. Global Remicade (Infliximab) Monoclonal Antibody Price by Application (2019-2024) & (US$/Unit)
Table 39. Global Remicade (Infliximab) Monoclonal Antibody Price by Application (2025-2030) & (US$/Unit)
Table 40. Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Region (2019-2024) & (US$ Million)
Table 42. Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Region (2025-2030) & (US$ Million)
Table 43. Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Region (2019-2024) & (%)
Table 44. Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Region (2025-2030) & (%)
Table 45. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
Table 46. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Region (2019-2024) & (K Units)
Table 47. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Region (2025-2030) & (K Units)
Table 48. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Region (2019-2024) & (%)
Table 49. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Region (2025-2030) & (%)
Table 50. Global Remicade (Infliximab) Monoclonal Antibody Average Price by Region (2019-2024) & (US$/Unit)
Table 51. Global Remicade (Infliximab) Monoclonal Antibody Average Price by Region (2025-2030) & (US$/Unit)
Table 52. Key Countries/Regions Remicade (Infliximab) Monoclonal Antibody Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 53. Key Countries/Regions Remicade (Infliximab) Monoclonal Antibody Sales Value, (2019-2024) & (US$ Million)
Table 54. Key Countries/Regions Remicade (Infliximab) Monoclonal Antibody Sales Value, (2025-2030) & (US$ Million)
Table 55. Key Countries/Regions Remicade (Infliximab) Monoclonal Antibody Sales Volume, (2019-2024) & (K Units)
Table 56. Key Countries/Regions Remicade (Infliximab) Monoclonal Antibody Sales Volume, (2025-2030) & (K Units)
Table 57. J & J Company Information
Table 58. J & J Introduction and Business Overview
Table 59. J & J Remicade (Infliximab) Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 60. J & J Remicade (Infliximab) Monoclonal Antibody Product Offerings
Table 61. J & J Recent Development
Table 62. Pfizer Company Information
Table 63. Pfizer Introduction and Business Overview
Table 64. Pfizer Remicade (Infliximab) Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 65. Pfizer Remicade (Infliximab) Monoclonal Antibody Product Offerings
Table 66. Pfizer Recent Development
Table 67. Organon Company Information
Table 68. Organon Introduction and Business Overview
Table 69. Organon Remicade (Infliximab) Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 70. Organon Remicade (Infliximab) Monoclonal Antibody Product Offerings
Table 71. Organon Recent Development
Table 72. Amgen Company Information
Table 73. Amgen Introduction and Business Overview
Table 74. Amgen Remicade (Infliximab) Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 75. Amgen Remicade (Infliximab) Monoclonal Antibody Product Offerings
Table 76. Amgen Recent Development
Table 77. Key Raw Materials Lists
Table 78. Raw Materials Key Suppliers Lists
Table 79. Remicade (Infliximab) Monoclonal Antibody Downstream Customers
Table 80. Remicade (Infliximab) Monoclonal Antibody Distributors List
Table 81. Research Programs/Design for This Report
Table 82. Key Data Information from Secondary Sources
Table 83. Key Data Information from Primary Sources
List of Figures
Figure 1. Remicade (Infliximab) Monoclonal Antibody Product Picture
Figure 2. Global Remicade (Infliximab) Monoclonal Antibody Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Remicade (Infliximab) Monoclonal Antibody Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume (2019-2030) & (K Units)
Figure 5. Global Remicade (Infliximab) Monoclonal Antibody Sales Price (2019-2030) & (US$/Unit)
Figure 6. Remicade (Infliximab) Monoclonal Antibody Report Years Considered
Figure 7. Global Remicade (Infliximab) Monoclonal Antibody Players Revenue Ranking (2023) & (US$ Million)
Figure 8. Global Remicade (Infliximab) Monoclonal Antibody Players Sales Volume Ranking (2023) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Remicade (Infliximab) Monoclonal Antibody Revenue in 2023
Figure 10. Remicade (Infliximab) Monoclonal Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 11. Brand Picture
Figure 12. Biosimilar Picture
Figure 13. Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 14. Global Remicade (Infliximab) Monoclonal Antibody Sales Value Market Share by Type, 2023 & 2030
Figure 15. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 16. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume Market Share by Type, 2023 & 2030
Figure 17. Global Remicade (Infliximab) Monoclonal Antibody Price by Type (2019-2030) & (US$/Unit)
Figure 18. Product Picture of Ankylosing Spondylitis
Figure 19. Product Picture of Rheumatoid Arthritis
Figure 20. Product Picture of Crohn’s Disease
Figure 21. Product Picture of Other
Figure 22. Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 23. Global Remicade (Infliximab) Monoclonal Antibody Sales Value Market Share by Application, 2023 & 2030
Figure 24. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
Figure 25. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume Market Share by Application, 2023 & 2030
Figure 26. Global Remicade (Infliximab) Monoclonal Antibody Price by Application (2019-2030) & (US$/Unit)
Figure 27. North America Remicade (Infliximab) Monoclonal Antibody Sales Value (2019-2030) & (US$ Million)
Figure 28. North America Remicade (Infliximab) Monoclonal Antibody Sales Value by Country (%), 2023 VS 2030
Figure 29. Europe Remicade (Infliximab) Monoclonal Antibody Sales Value (2019-2030) & (US$ Million)
Figure 30. Europe Remicade (Infliximab) Monoclonal Antibody Sales Value by Country (%), 2023 VS 2030
Figure 31. Asia Pacific Remicade (Infliximab) Monoclonal Antibody Sales Value (2019-2030) & (US$ Million)
Figure 32. Asia Pacific Remicade (Infliximab) Monoclonal Antibody Sales Value by Country (%), 2023 VS 2030
Figure 33. South America Remicade (Infliximab) Monoclonal Antibody Sales Value (2019-2030) & (US$ Million)
Figure 34. South America Remicade (Infliximab) Monoclonal Antibody Sales Value by Country (%), 2023 VS 2030
Figure 35. Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Sales Value (2019-2030) & (US$ Million)
Figure 36. Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Sales Value by Country (%), 2023 VS 2030
Figure 37. Key Countries/Regions Remicade (Infliximab) Monoclonal Antibody Sales Value (%), (2019-2030)
Figure 38. Key Countries/Regions Remicade (Infliximab) Monoclonal Antibody Sales Volume (%), (2019-2030)
Figure 39. United States Remicade (Infliximab) Monoclonal Antibody Sales Value, (2019-2030) & (US$ Million)
Figure 40. United States Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (%), 2023 VS 2030
Figure 41. United States Remicade (Infliximab) Monoclonal Antibody Sales Value by Application (%), 2023 VS 2030
Figure 42. Europe Remicade (Infliximab) Monoclonal Antibody Sales Value, (2019-2030) & (US$ Million)
Figure 43. Europe Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (%), 2023 VS 2030
Figure 44. Europe Remicade (Infliximab) Monoclonal Antibody Sales Value by Application (%), 2023 VS 2030
Figure 45. China Remicade (Infliximab) Monoclonal Antibody Sales Value, (2019-2030) & (US$ Million)
Figure 46. China Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (%), 2023 VS 2030
Figure 47. China Remicade (Infliximab) Monoclonal Antibody Sales Value by Application (%), 2023 VS 2030
Figure 48. Japan Remicade (Infliximab) Monoclonal Antibody Sales Value, (2019-2030) & (US$ Million)
Figure 49. Japan Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (%), 2023 VS 2030
Figure 50. Japan Remicade (Infliximab) Monoclonal Antibody Sales Value by Application (%), 2023 VS 2030
Figure 51. South Korea Remicade (Infliximab) Monoclonal Antibody Sales Value, (2019-2030) & (US$ Million)
Figure 52. South Korea Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (%), 2023 VS 2030
Figure 53. South Korea Remicade (Infliximab) Monoclonal Antibody Sales Value by Application (%), 2023 VS 2030
Figure 54. Southeast Asia Remicade (Infliximab) Monoclonal Antibody Sales Value, (2019-2030) & (US$ Million)
Figure 55. Southeast Asia Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (%), 2023 VS 2030
Figure 56. Southeast Asia Remicade (Infliximab) Monoclonal Antibody Sales Value by Application (%), 2023 VS 2030
Figure 57. India Remicade (Infliximab) Monoclonal Antibody Sales Value, (2019-2030) & (US$ Million)
Figure 58. India Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (%), 2023 VS 2030
Figure 59. India Remicade (Infliximab) Monoclonal Antibody Sales Value by Application (%), 2023 VS 2030
Figure 60. Remicade (Infliximab) Monoclonal Antibody Industrial Chain
Figure 61. Remicade (Infliximab) Monoclonal Antibody Manufacturing Cost Structure
Figure 62. Channels of Distribution (Direct Sales, and Distribution)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Table 1. Remicade (Infliximab) Monoclonal Antibody Market Trends
Table 2. Remicade (Infliximab) Monoclonal Antibody Market Drivers & Opportunity
Table 3. Remicade (Infliximab) Monoclonal Antibody Market Challenges
Table 4. Remicade (Infliximab) Monoclonal Antibody Market Restraints
Table 5. Global Remicade (Infliximab) Monoclonal Antibody Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Remicade (Infliximab) Monoclonal Antibody Revenue Market Share by Company (2019-2024)
Table 7. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Company (2019-2024) & (K Units)
Table 8. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume Market Share by Company (2019-2024)
Table 9. Global Market Remicade (Infliximab) Monoclonal Antibody Price by Company (2019-2024) & (US$/Unit)
Table 10. Key Manufacturers Remicade (Infliximab) Monoclonal Antibody Manufacturing Base Distribution and Headquarters
Table 11. Key Manufacturers Remicade (Infliximab) Monoclonal Antibody Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Remicade (Infliximab) Monoclonal Antibody
Table 13. Global Remicade (Infliximab) Monoclonal Antibody Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Remicade (Infliximab) Monoclonal Antibody as of 2023)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share in Value by Type (2019-2024) & (%)
Table 20. Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share in Value by Type (2025-2030) & (%)
Table 21. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
Table 22. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Type (2019-2024) & (K Units)
Table 23. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Type (2025-2030) & (K Units)
Table 24. Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share in Volume by Type (2019-2024) & (%)
Table 25. Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share in Volume by Type (2025-2030) & (%)
Table 26. Global Remicade (Infliximab) Monoclonal Antibody Price by Type (2019-2024) & (US$/Unit)
Table 27. Global Remicade (Infliximab) Monoclonal Antibody Price by Type (2025-2030) & (US$/Unit)
Table 28. Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Application (2019-2024) & (US$ Million)
Table 30. Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Application (2025-2030) & (US$ Million)
Table 31. Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share in Value by Application (2019-2024) & (%)
Table 32. Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share in Value by Application (2025-2030) & (%)
Table 33. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
Table 34. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Application (2019-2024) & (K Units)
Table 35. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Application (2025-2030) & (K Units)
Table 36. Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share in Volume by Application (2019-2024) & (%)
Table 37. Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share in Volume by Application (2025-2030) & (%)
Table 38. Global Remicade (Infliximab) Monoclonal Antibody Price by Application (2019-2024) & (US$/Unit)
Table 39. Global Remicade (Infliximab) Monoclonal Antibody Price by Application (2025-2030) & (US$/Unit)
Table 40. Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Region (2019-2024) & (US$ Million)
Table 42. Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Region (2025-2030) & (US$ Million)
Table 43. Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Region (2019-2024) & (%)
Table 44. Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Region (2025-2030) & (%)
Table 45. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
Table 46. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Region (2019-2024) & (K Units)
Table 47. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Region (2025-2030) & (K Units)
Table 48. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Region (2019-2024) & (%)
Table 49. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Region (2025-2030) & (%)
Table 50. Global Remicade (Infliximab) Monoclonal Antibody Average Price by Region (2019-2024) & (US$/Unit)
Table 51. Global Remicade (Infliximab) Monoclonal Antibody Average Price by Region (2025-2030) & (US$/Unit)
Table 52. Key Countries/Regions Remicade (Infliximab) Monoclonal Antibody Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 53. Key Countries/Regions Remicade (Infliximab) Monoclonal Antibody Sales Value, (2019-2024) & (US$ Million)
Table 54. Key Countries/Regions Remicade (Infliximab) Monoclonal Antibody Sales Value, (2025-2030) & (US$ Million)
Table 55. Key Countries/Regions Remicade (Infliximab) Monoclonal Antibody Sales Volume, (2019-2024) & (K Units)
Table 56. Key Countries/Regions Remicade (Infliximab) Monoclonal Antibody Sales Volume, (2025-2030) & (K Units)
Table 57. J & J Company Information
Table 58. J & J Introduction and Business Overview
Table 59. J & J Remicade (Infliximab) Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 60. J & J Remicade (Infliximab) Monoclonal Antibody Product Offerings
Table 61. J & J Recent Development
Table 62. Pfizer Company Information
Table 63. Pfizer Introduction and Business Overview
Table 64. Pfizer Remicade (Infliximab) Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 65. Pfizer Remicade (Infliximab) Monoclonal Antibody Product Offerings
Table 66. Pfizer Recent Development
Table 67. Organon Company Information
Table 68. Organon Introduction and Business Overview
Table 69. Organon Remicade (Infliximab) Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 70. Organon Remicade (Infliximab) Monoclonal Antibody Product Offerings
Table 71. Organon Recent Development
Table 72. Amgen Company Information
Table 73. Amgen Introduction and Business Overview
Table 74. Amgen Remicade (Infliximab) Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 75. Amgen Remicade (Infliximab) Monoclonal Antibody Product Offerings
Table 76. Amgen Recent Development
Table 77. Key Raw Materials Lists
Table 78. Raw Materials Key Suppliers Lists
Table 79. Remicade (Infliximab) Monoclonal Antibody Downstream Customers
Table 80. Remicade (Infliximab) Monoclonal Antibody Distributors List
Table 81. Research Programs/Design for This Report
Table 82. Key Data Information from Secondary Sources
Table 83. Key Data Information from Primary Sources
List of Figures
Figure 1. Remicade (Infliximab) Monoclonal Antibody Product Picture
Figure 2. Global Remicade (Infliximab) Monoclonal Antibody Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Remicade (Infliximab) Monoclonal Antibody Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume (2019-2030) & (K Units)
Figure 5. Global Remicade (Infliximab) Monoclonal Antibody Sales Price (2019-2030) & (US$/Unit)
Figure 6. Remicade (Infliximab) Monoclonal Antibody Report Years Considered
Figure 7. Global Remicade (Infliximab) Monoclonal Antibody Players Revenue Ranking (2023) & (US$ Million)
Figure 8. Global Remicade (Infliximab) Monoclonal Antibody Players Sales Volume Ranking (2023) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Remicade (Infliximab) Monoclonal Antibody Revenue in 2023
Figure 10. Remicade (Infliximab) Monoclonal Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 11. Brand Picture
Figure 12. Biosimilar Picture
Figure 13. Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 14. Global Remicade (Infliximab) Monoclonal Antibody Sales Value Market Share by Type, 2023 & 2030
Figure 15. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 16. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume Market Share by Type, 2023 & 2030
Figure 17. Global Remicade (Infliximab) Monoclonal Antibody Price by Type (2019-2030) & (US$/Unit)
Figure 18. Product Picture of Ankylosing Spondylitis
Figure 19. Product Picture of Rheumatoid Arthritis
Figure 20. Product Picture of Crohn’s Disease
Figure 21. Product Picture of Other
Figure 22. Global Remicade (Infliximab) Monoclonal Antibody Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 23. Global Remicade (Infliximab) Monoclonal Antibody Sales Value Market Share by Application, 2023 & 2030
Figure 24. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
Figure 25. Global Remicade (Infliximab) Monoclonal Antibody Sales Volume Market Share by Application, 2023 & 2030
Figure 26. Global Remicade (Infliximab) Monoclonal Antibody Price by Application (2019-2030) & (US$/Unit)
Figure 27. North America Remicade (Infliximab) Monoclonal Antibody Sales Value (2019-2030) & (US$ Million)
Figure 28. North America Remicade (Infliximab) Monoclonal Antibody Sales Value by Country (%), 2023 VS 2030
Figure 29. Europe Remicade (Infliximab) Monoclonal Antibody Sales Value (2019-2030) & (US$ Million)
Figure 30. Europe Remicade (Infliximab) Monoclonal Antibody Sales Value by Country (%), 2023 VS 2030
Figure 31. Asia Pacific Remicade (Infliximab) Monoclonal Antibody Sales Value (2019-2030) & (US$ Million)
Figure 32. Asia Pacific Remicade (Infliximab) Monoclonal Antibody Sales Value by Country (%), 2023 VS 2030
Figure 33. South America Remicade (Infliximab) Monoclonal Antibody Sales Value (2019-2030) & (US$ Million)
Figure 34. South America Remicade (Infliximab) Monoclonal Antibody Sales Value by Country (%), 2023 VS 2030
Figure 35. Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Sales Value (2019-2030) & (US$ Million)
Figure 36. Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Sales Value by Country (%), 2023 VS 2030
Figure 37. Key Countries/Regions Remicade (Infliximab) Monoclonal Antibody Sales Value (%), (2019-2030)
Figure 38. Key Countries/Regions Remicade (Infliximab) Monoclonal Antibody Sales Volume (%), (2019-2030)
Figure 39. United States Remicade (Infliximab) Monoclonal Antibody Sales Value, (2019-2030) & (US$ Million)
Figure 40. United States Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (%), 2023 VS 2030
Figure 41. United States Remicade (Infliximab) Monoclonal Antibody Sales Value by Application (%), 2023 VS 2030
Figure 42. Europe Remicade (Infliximab) Monoclonal Antibody Sales Value, (2019-2030) & (US$ Million)
Figure 43. Europe Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (%), 2023 VS 2030
Figure 44. Europe Remicade (Infliximab) Monoclonal Antibody Sales Value by Application (%), 2023 VS 2030
Figure 45. China Remicade (Infliximab) Monoclonal Antibody Sales Value, (2019-2030) & (US$ Million)
Figure 46. China Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (%), 2023 VS 2030
Figure 47. China Remicade (Infliximab) Monoclonal Antibody Sales Value by Application (%), 2023 VS 2030
Figure 48. Japan Remicade (Infliximab) Monoclonal Antibody Sales Value, (2019-2030) & (US$ Million)
Figure 49. Japan Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (%), 2023 VS 2030
Figure 50. Japan Remicade (Infliximab) Monoclonal Antibody Sales Value by Application (%), 2023 VS 2030
Figure 51. South Korea Remicade (Infliximab) Monoclonal Antibody Sales Value, (2019-2030) & (US$ Million)
Figure 52. South Korea Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (%), 2023 VS 2030
Figure 53. South Korea Remicade (Infliximab) Monoclonal Antibody Sales Value by Application (%), 2023 VS 2030
Figure 54. Southeast Asia Remicade (Infliximab) Monoclonal Antibody Sales Value, (2019-2030) & (US$ Million)
Figure 55. Southeast Asia Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (%), 2023 VS 2030
Figure 56. Southeast Asia Remicade (Infliximab) Monoclonal Antibody Sales Value by Application (%), 2023 VS 2030
Figure 57. India Remicade (Infliximab) Monoclonal Antibody Sales Value, (2019-2030) & (US$ Million)
Figure 58. India Remicade (Infliximab) Monoclonal Antibody Sales Value by Type (%), 2023 VS 2030
Figure 59. India Remicade (Infliximab) Monoclonal Antibody Sales Value by Application (%), 2023 VS 2030
Figure 60. Remicade (Infliximab) Monoclonal Antibody Industrial Chain
Figure 61. Remicade (Infliximab) Monoclonal Antibody Manufacturing Cost Structure
Figure 62. Channels of Distribution (Direct Sales, and Distribution)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Smart Potentiometric Titrator - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Nov 05, 24
Multifunctional Zeta Potential Analyzer - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Nov 05, 24
Ultrapure Water pH Sensor - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Nov 05, 24
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232